This event is a one-of-a-kind, interactive forum where top diligence experts will discuss best practices and strategies for executing a proper IP due diligence analysis, both for your own portfolio, and that of potential targets.


The continued success of a life science company hinges upon successful partnerships — There are many corporate transactions involving life sciences IP that necessitate conducting due diligence. For example, you may be asked to engage your team members in the face of a merger or acquisition, an IPO, venture capital financing, in-licensing, partnering, co-development, or distribution agreements. How you structure your diligence is entirely dependent upon your objectives.

ACI’s 3rd Annual Summit on Life Sciences IP Due Diligence provides a forum for key industry stakeholders to master how to cultivate, navigate, and apply the results of an effective and profitable due diligence analysis.

Download the Complete Agenda and Faculty List Now!



TAILOR your life sciences IP due diligence checklist for 2020

LEARN firsthand from industry thought leaders on how to perfect the FTO search

ANALYZE the latest filings, rulings and legislative developments impacting life sciences IP due diligence

DEVELOP strategies for assessing, valuing and commercializing IP assets




Donna Meuth

Donna Meuth

Associate General Counsel, Intellectual Property
Eisai Inc.

“I’m excited to Co-Chair ACI’s Life Sciences IP Due Diligence conference in Boston this year. The conference offers a great opportunity to gain advice from experts in the field and learn how to avoid issues and mitigate risk in IP due diligences. It’s great to have a conference aimed specifically to the life sciences in view of the many complexities that arise in our transactions.”

Timothy Witkowski

Timothy Witkowski

Global Head, Chemistry Patents
Novartis Institutes for BioMedical Research (NIBR)

“M&A and licensing practice tests the skills of IP attorneys with novel and difficult issues. I am pleased to Co-Chair ACI’s Life Sciences IP Due Diligence conference because it is a great resource for those who practice in this area by focusing on that crucial piece of any life science company’s strategy: how to properly identify, value, and leverage IP through a potential transaction with another party.”

Whether you are the acquirer or the target, our faculty of thought leaders will provide you with proven strategies you can immediately incorporate into your practice, including representation from senior executives and corporate counsel at: Aptevo Therapeutics, Celgene, Eisai Inc., Fresenius Kabi USA, Kintai Therapeutics, Novartis Institutes for BioMedical Research (NIBR), Pfizer Inc., Roche, Takeda Pharmaceutical, Wave Life Sciences and many more. They will share best practices and expert strategies for assessing, valuing, and commercializing IP assets to enable your company to advance its key business development goals, during newly designed sessions including:

  • Identifying Business Objectives, Assembling the Players and Preparing the IP Due Diligence Checklist for Non-M&A Transactions
  • Avoiding Missteps During the Chain of Title Review: Understanding Ownership Rules
  • Mastering the FTO Search: Identifying the Metes and Bounds to Save Time and Money
  • Valuation and Intellectual Property: The Real Driving Force Behind the Deal
  • Mitigating M&A Risk Through Improved Due Diligence: A Case Study from Both the Target and Acquirer Perspectives
  • Analyzing Legal, Regulatory and Legislative Developments Influencing IP Due Diligence
  • The Benefits of Partnering with PE Firms and Venture Capitalists
  • The Global Approach to Entering into Transactions: Mitigating International Legal Risks Presented in Life Sciences
  • When Faulty IP Due Diligence Kills the Deal: If I Knew Then What I Know Now

Reserve your seat today by calling 888-224-2480 or


  • AMRI
  • Akin Gump Strauss Hauer & Feld LLP
  • Allergan plc
  • Arnold & Porter Kaye Scholer LLP
  • AtriCure Inc
  • Axinn Veltrop & Harkrider LLP
  • BA Ruskin Law LLC
  • BONWRx
  • Beck & Thomas
  • Biogen
  • Blaze Bioscience Inc
  • Boehringer Ingelheim GmbH
  • Boehringer Ingelheim International GmbH
  • Brammer Bio
  • Brinks Gilson & Lione
  • Cantor Colburn LLP
  • Carlson Caspers Vandenburgh Lindquist & Schuman PA
  • Centre for Drug Research and Development
  • Charles River Associates Inc
  • Choate Hall & Stewart LLP
  • Cipla Limited
  • Clark & Elbing LLP
  • Codiak BioSciences
  • DRI Capital Inc
  • Dentsply Sirona Inc
  • Dr. Reddys Laboratories
  • Drinker Biddle & Reath LLP
  • Duane Morris LLP
  • Eisai Inc
  • Evolve BioSystems
  • Finnegan Henderson Farabow Garrett & Dunner
  • Fish & Richardson
  • Fitzpatrick Cella Harper & Scinto
  • Foghorn Therapeutics
  • Forma Therapeutics Inc
  • Futuragene
  • Genentech Inc
  • Gibson Dunn & Crutcher LLP
  • Gilead Sciences
  • Green Griffith & Borg-Breen LLP
  • Heliae
  • Hikma Pharmaceuticals USA Inc
  • Houlihan Lokey
  • Hueschen & Sage PLLC
  • Immunogen Inc
  • Indivior Inc
  • Intellia Therapeutics Inc
  • Ipsen Bioscience Inc
  • Ironwood Pharmaceuticals Inc
  • Jazz Pharmaceuticals
  • Johnson-IP Strategy & Policy Consulting
  • Jounce Therapeutics Inc
  • KSQ Therapeutics Inc
  • King & Spalding LLP
  • Leason Ellis LLP
  • MEDRx
  • Marshall Gerstein & Borun LLP
  • Mayer Brown LLP
  • McDonnell Boehnen Hulbert & Berghoff LLP
  • Merchant & Gould
  • Merck & Co
  • MicroVention Inc.
  • Norris McLaughlin & Marcus P.A.
  • Novartis
  • Novartis Institutes For Biomedical Research
  • Novartis Pharmaceuticals
  • Obalon Therapeutics
  • Ohlandt Greely Ruggiero & Perle LLP
  • Paul Hastings LLP
  • Pearne & Gordon LLP
  • Pepper Hamilton LLP
  • Pieris Pharmaceuticals Inc
  • Porzio Bromberg & Newman P.C.
  • Purdue Pharma LP
  • Purdue Research Foundation
  • Regeneron Pharmaceuticals Inc
  • Roivant Sciences Inc
  • Ropes & Gray LLP
  • Rutgers Law School
  • Sarepta Therapeutics
  • Shire Pharmaceuticals
  • SmartPharm Therapeutics
  • Squire Patton Boggs Us LLP
  • Steptoe & Johnson LLP
  • Sterne Kessler Goldstein & Fox
  • Sun Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Transformative
  • US Court of Appeals for Federal Circuit
  • University of California
  • VBI Vaccines Inc
  • VLP Law Group LLP
  • Wave Life Sciences
  • Wilson Sonsini Goodrich & Rosati PC

Hear what past participants have to say about this one-of-a-kind event:

“Unique high level sessions, good mix of in-house and outside counsel”
“Hearing from professionals involved in due diligence on a daily basis was very informative.”
“Great panels, lots of diversity of practice, and lots of seasoned practitioners”
“The design of the event brought us all together along with room intimacy”
“High quality and level of conversations”
“Awesome- Interactive and thorough information”
“Good focused discussions covering all aspects”

ACI’s Global Series of Life Sciences conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy. Learn More

Event Contacts

Sponsorship Opportunities:

American Conference Institute
Email Us

Media Partnership Opportunities:

Linda Lam
Email Us

Program and Speaking Opportunities:

Joseph Gallagher
Email Us